luigi fattore
luigi fattore
PostDoc presso Istituto Nazionale Tumori Regina Elena
No verified email
Title
Cited by
Cited by
Year
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
P Ponikowski, BA Kirwan, SD Anker, T McDonagh, M Dorobantu, ...
The Lancet 396 (10266), 1895-1904, 2020
1102020
miR-579-3p controls melanoma progression and resistance to target therapy
L Fattore, R Mancini, M Acunzo, G Romano, A Laganą, ME Pisanu, ...
Proceedings of the National Academy of Sciences 113 (34), E5005-E5013, 2016
822016
MicroRNAs in melanoma development and resistance to target therapy
L Fattore, S Costantini, D Malpicci, CF Ruggiero, PA Ascierto, CM Croce, ...
Oncotarget 8 (13), 22262, 2017
792017
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
L Fattore, E Marra, ME Pisanu, A Noto, C de Vitis, F Belleudi, L Aurisicchio, ...
Journal of translational medicine 11 (1), 1-11, 2013
662013
Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry
JP Bassand, S Virdone, SZ Goldhaber, AJ Camm, DA Fitzmaurice, ...
Circulation 139 (6), 787-798, 2019
472019
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer
A Noto, C De Vitis, G Roscilli, L Fattore, D Malpicci, E Marra, L Luberto, ...
Oncotarget 4 (8), 1253, 2013
372013
Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells
F Belleudi, E Marra, F Mazzetta, L Fattore, MR Giovagnoli, R Mancini, ...
Cell Cycle 11 (7), 1455-1467, 2012
372012
Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
L Fattore, CF Ruggiero, ME Pisanu, D Liguoro, A Cerri, S Costantini, ...
Cell Death & Differentiation 26 (7), 1267-1282, 2019
332019
Selective targeting of point-mutated KRAS through artificial microRNAs
M Acunzo, G Romano, G Nigita, D Veneziano, L Fattore, A Laganą, ...
Proceedings of the National Academy of Sciences 114 (21), E4203-E4212, 2017
322017
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
ME Pisanu, M Maugeri-Saccą, L Fattore, S Bruschini, C De Vitis, E Tabbģ, ...
Journal of Experimental & Clinical Cancer Research 37 (1), 1-17, 2018
292018
Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR)
P Costanzo, A Santini, L Fattore, E Novellino, A Ritieni
Food and Chemical Toxicology 76, 77-79, 2015
292015
TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung
A Ricci*, C De Vitis*, A Noto*, L Fattore, S Mariotta, E Cherubini, G Roscilli, ...
Cell cycle 12 (11), 1696-1703, 2013
292013
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
L Fattore, D Malpicci, E Marra, F Belleudi, A Noto, C De Vitis, ME Pisanu, ...
Oncotarget 6 (28), 24823, 2015
282015
Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
L Fattore, CF Ruggiero, D Liguoro, R Mancini, G Ciliberto
Cell death & disease 10 (11), 1-12, 2019
232019
Management and 1‐year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD‐AF registry
S Goto, P Angchaisuksiri, JP Bassand, AJ Camm, H Dominguez, ...
Journal of the American Heart Association 8 (3), e010510, 2019
232019
Role of WT1–ZNF224 interaction in the expression of apoptosis-regulating genes
G Montano, E Cesaro, L Fattore, K Vidovic, C Palladino, R Crescitelli, ...
Human molecular genetics 22 (9), 1771-1782, 2013
222013
MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma
L Fattore, A Sacconi, R Mancini, G Ciliberto
Cytokine & growth factor reviews 36, 39-48, 2017
202017
Indications for dual-chamber cardioverter defibrillators at implant and at 1 year follow-up: a retrospective analysis in the single-chamber defibrillator era
A Proclemer, P Della Bella, D Facchin, L Fattore, C Carbucicchio, ...
EP Europace 3 (2), 132-135, 2001
202001
ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma: Early detection in CTCs during therapy and insights into regulation by …
CF Ruggiero, D Malpicci, L Fattore, G Madonna, V Vanella, D Mallardo, ...
Cancers 11 (10), 1425, 2019
162019
CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions
S Bruschini, S di Martino, ME Pisanu, L Fattore, C De Vitis, V Laquintana, ...
Journal of cellular physiology 235 (3), 1877-1887, 2020
152020
The system can't perform the operation now. Try again later.
Articles 1–20